AYTU BIOPHARMA, INC Debt Related Commitment Fees and Debt Issuance Costs
AYTU BIOPHARMA, INC (AYTU) reported Debt Related Commitment Fees and Debt Issuance Costs of $20.00 thousand for the 12-month period ending 2017-06-30, per its 10-K filed 2017-08-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts · last filed 2017-08-31
- AYTU BIOPHARMA, INC debt related commitment fees and debt issuance costs for the quarter ending 2017-06-30 was $0.00.
- AYTU BIOPHARMA, INC debt related commitment fees and debt issuance costs for the quarter ending 2017-03-31 was $0.00.
- AYTU BIOPHARMA, INC debt related commitment fees and debt issuance costs for the quarter ending 2016-12-31 was $0.00.
- AYTU BIOPHARMA, INC debt related commitment fees and debt issuance costs for the quarter ending 2016-09-30 was $20.00K.
- AYTU BIOPHARMA, INC debt related commitment fees and debt issuance costs for fiscal 2017 was $20.00K, a 0.00% change from fiscal 2016.
- AYTU BIOPHARMA, INC debt related commitment fees and debt issuance costs for fiscal 2016 was $20.00K.
| Period end | Debt Related Commitment Fees and Debt Issuance Costs 3 month | Debt Related Commitment Fees and Debt Issuance Costs 6 month | Debt Related Commitment Fees and Debt Issuance Costs 9 month | Debt Related Commitment Fees and Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2017-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-31 | $0.00 derived: sum of 2 quarters · filed 2017-08-31 | $0.00 derived: sum of 3 quarters · filed 2017-08-31 | $20.00K 10-K · filed 2017-08-31 |
| 2017-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-11 | $0.00 derived: sum of 2 quarters · filed 2017-05-11 | $20.00K 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09 | $20.00K 10-Q · filed 2017-02-09 | ||
| 2016-09-30 | $20.00K 10-Q · filed 2016-11-07 | |||
| 2016-06-30 | $20.00K 10-K · filed 2016-09-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |